Capital International Sarl Sells 19,931 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Capital International Sarl lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 115,142 shares of the biopharmaceutical company's stock after selling 19,931 shares during the quarter. Capital International Sarl owned about 0.09% of Alnylam Pharmaceuticals worth $27,094,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Larson Financial Group LLC grew its holdings in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Versant Capital Management Inc raised its position in shares of Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 83 shares in the last quarter. Finally, IFP Advisors Inc grew its position in shares of Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now directly owns 14,321 shares of the company's stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 in the last quarter. Insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ALNY. Redburn Atlantic assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price objective for the company. Citigroup increased their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Needham & Company LLC reissued a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Chardan Capital restated a "buy" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Sanford C. Bernstein lowered their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the company's stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

Alnylam Pharmaceuticals Stock Up 1.6 %

NASDAQ ALNY traded up $3.72 on Wednesday, reaching $240.47. The stock had a trading volume of 290,767 shares, compared to its average volume of 872,052. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The business has a 50 day moving average price of $247.91 and a 200 day moving average price of $256.50. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a market capitalization of $31.28 billion, a price-to-earnings ratio of -110.82 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.